β-微管蛋白Ⅰ基因突变与多烯紫杉醇治疗晚期非小细胞肺癌耐药的相关性研究  

Association between class Ⅰ β-tubulin gene mutation and drug resistance of docetaxel in the treatment of advanced non-small cell lung cancer

作　　者：陈庆恺[1] 柳青[1] 丁艳辉[1] 吴亚梅[2] 冯燕梅[2] 

机构地区：[1]重庆医科大学附属第一医院临床研究中心,重庆400016 [2]重庆医科大学附属第一医院呼吸内科,重庆400016

出　　处：《重庆医科大学学报》2013年第9期1017-1021,共5页Journal of Chongqing Medical University

摘　　要：目的:探讨β-微管蛋白Ⅰ编码基因TUBB基因的突变与多烯紫杉醇治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)耐药是否具有相关性。方法:用聚合酶链反应(polymerase chain reaction,PCR)和核苷酸测序技术检测90例晚期NSCLC患者TUBB基因是否存在突变。结果:36例患者在TUBB第4号外显子的第147号氨基酸编码序列处出现点突变,但这一突变与患者化疗疗效无明显相关。结论:β-微管蛋白Ⅰ的编码基因TUBB第4号外显子的第147号氨基酸编码序列的改变与多烯紫杉醇治疗NSCLC耐药无明显相关,但在患者中观察到了TUBB基因新的突变形式,该突变是否会对微管蛋白的结构和功能产生影响尚不确定,还需进一步深入研究。Objective：To investigate the association between the mutation of the encoding gene of class I β-tubulin （TUBB） and the drug resistance of docetaxel in the treatment of non-small cell lung cancer（NSCLC）. Methods：Polymerase chain reaction（PCR） andnucleotide sequencing were used to test whether mutation existed in 90 advanced NSCLC patients. Results：A mutation at the fourth ex- on of TUBB encoding sequence which encoding the 147th amino acid was found in 36 patients, but it was not significantly associated with the chemotherapy effect of decetaxel treatment for NSCLC. Conclusions ： Mutation at the fourth exon of TUBB gene is not asso- ciated with the resistance of decetaxe｜ treatment for NSCLC patients. Further investigation should be done to verify whether the struc- ture and function of tubulin would be affected by this mutation.

关 键 词：非小细胞肺癌 多烯紫杉醇 β-微管蛋白I 点突变 

分 类 号：R394.3[医药卫生—医学遗传学]